The story of the erectile dysfunction drug presents a intricate picture for investors. While the initial launch generated significant profits, the end of its exclusive rights opened the door to cheaper competitors, https://nybookmark.com/story23575168/sildenafil-and-the-pharmaceutical-industry-a-volatile-investment